Evidence map›Paper›PMID 37228942›Full record

ArticleAnnals of medicine and surgery (2012)2023

Prospective, multicenter study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (XenMatrix™ AB Surgical Graft) for hernia repair in all centers for disease control and prevention wound classes: 24-month follow-up cohort.

Obeid N Ilahi, George Velmahos, Jeffrey E Janis, Stephen J Kovach, Susan F McLean, Reza Askari, Courtney A Sommer, Suresh Agarwal, Jahnavi Srinivasan, Alex K Wong and 9 more

Abstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Obeid N IlahiWashington University School of Medicine.ORCID 0000-0003-0719-2554
George VelmahosMassachusetts General Hospital.
Jeffrey E JanisThe Ohio State University, Columbus, OH.ORCID 0000-0001-6103-4798
Stephen J KovachUniversity of Pennsylvania, Philadelphia, PA.
Susan F McLeanTexas Tech University Health Science Center School of Medicine, El Paso, TX.ORCID 0000-0002-9659-1727
Reza AskariBrigham and Women's Hospital, Boston, MA.
Courtney A SommerDuke University Medical Center, Durham, NC.
Suresh AgarwalDuke University Medical Center, Durham, NC.
Jahnavi SrinivasanEmory University, Atlanta, GA.ORCID 0000-0002-3215-8211
Alex K WongCity of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-4068-5230
Andrea PakulaKern Medical, Bakersfield.
Edward P MirandaUniversity of California San Francisco, San Francisco, CA.
Kerry BreenMassachusetts General Hospital.ORCID 0000-0002-1177-3493
Mark ShapiroDuke University Medical Center, Durham, NC.
Corey R DeekenCovalent Bio, LLC, St. Louis, MO.ORCID 0000-0002-5722-4473
R Cody StringerCovalent Bio, LLC, St. Louis, MO.
J Reed McGrawUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0003-2394-2212
Corey BasconeUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5396-0385
Robert G MartindaleOregon Health & Science University, Portland, OR.ORCID 0000-0002-9159-4486

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prospective, multicenter, single-arm study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (AC-PDM) in a cohort involving all centers for disease control and prevention wound classes in ventral/incisional midline hernia repair (VIHR). Materials and methods: Seventy-five patients (mean age 58.6±12.7 years; BMI 31.3±4.9 kg/m Results: 14.7% of patients experienced SSO requiring intervention within 45 days post-implantation, and 20.0% thereafter (>45 d post-implantation). Recurrence (5.8%), definitely device-related adverse events (4.0%), and reoperation (10.7%) were low at 24 months; all quality-of-life indicators were significantly improved compared to baseline. Conclusion: AC-PDM exhibited favourable results, including infrequent hernia recurrence and definitely device-related adverse events, with reoperation and SSO comparable to other studies, and significantly improved quality of life.

Indexed as

hernia repairminocyclineporcine dermal matrixrifampinsurgical site occurrenceXenMatrix AB surgical graft

Identifiers

PMID37228942
PMCPMC10205341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.